Literature DB >> 2795037

The natural course of myasthenia gravis: a long term follow up study.

H J Oosterhuis1.   

Abstract

A long term follow up study is presented of 73 patients with myasthenia gravis, living in Amsterdam between 1926 and 1965. In the period 1961-65 the annual incidence was 3.1, the prevalence 53 per million. Maximum severity of the disease occurred during the first seven years after onset in 87%. Eighteen (29%) patients died, of whom eight had a thymoma (TH). Spontaneous improvement or remission occurred at any time during the follow up. At the end of the study (1985) 16 (22%) patients were in a complete clinical remission, 13 (18%) had improved considerably (3 with prednisone), 12 (16%) had improved moderately, 12 (16%) had remained unchanged and two had deteriorated. If the early deaths are excluded the outcome is similar in the early and the late onset group without TH. Patients with TH had a less favourable course. Associated autoimmune diseases were diagnosed in 25% (n = 58). Because most of these patients were treated with anticholinesterases only, the evolution of their clinical state represents the natural course of MG.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795037      PMCID: PMC1031695          DOI: 10.1136/jnnp.52.10.1121

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  An evaluation of thymectomy in myasthenia gravis.

Authors:  J A SIMPSON
Journal:  Brain       Date:  1958-03       Impact factor: 13.501

2.  Neonatal myasthenia gravis: report of two cases and review of the literature.

Authors:  T Namba; S B Brown; D Grob
Journal:  Pediatrics       Date:  1970-03       Impact factor: 7.124

3.  Graves' disease in Olmsted County, Minnesota, 1935 through 1967.

Authors:  J Furszyfer; L T Kurland; W M McConahey; L R Elveback
Journal:  Mayo Clin Proc       Date:  1970-09       Impact factor: 7.616

4.  The natural course of myasthenia gravis and effect of therapeutic measures.

Authors:  D Grob; N G Brunner; T Namba
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

5.  The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality.

Authors:  A Linos; J W Worthington; W M O'Fallon; L T Kurland
Journal:  Am J Epidemiol       Date:  1980-01       Impact factor: 4.897

Review 6.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

7.  Genetic aspects in myasthenia gravis. A family study of 264 Finnish patients.

Authors:  R Pirskanen
Journal:  Acta Neurol Scand       Date:  1977-11       Impact factor: 3.209

8.  Epidemiology of myasthenia gravis in Norway.

Authors:  A Storm-Mathisen
Journal:  Acta Neurol Scand       Date:  1984-10       Impact factor: 3.209

9.  Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study.

Authors:  H Oosterhuis; J Bethlem
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-04       Impact factor: 10.154

10.  Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients.

Authors:  P C Limburg; T H The; E Hummel-Tappel; H J Oosterhuis
Journal:  J Neurol Sci       Date:  1983-03       Impact factor: 3.181

View more
  55 in total

1.  Strabismus surgery in the management of diplopia caused by myasthenia gravis.

Authors:  O C Morris; J O'Day
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

Review 4.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 5.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

6.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

7.  Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.

Authors:  Zhao Xiaoyan; R Pirskanen; V Malmstrom; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 8.  Thymectomy for myasthenia gravis.

Authors:  J D Urschel; R P Grewal
Journal:  Postgrad Med J       Date:  1998-03       Impact factor: 2.401

Review 9.  The natural course of myasthenia gravis.

Authors:  V Fonseca; C W Havard
Journal:  BMJ       Date:  1990-06-02

10.  Thymectomy for myasthenia gravis: what we know and what we don't.

Authors:  Carlos E Bravo-Iñiguez; Michael T Jaklitsch
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.